Innovating Cell Therapy Manufacturing

aCGT Vector

Apr 9, 2021PAO-04-22-R221-09

At a Dublin, Ireland stop on the Road to 2021 trans-European road trip, Gary McAuslan, Founder and CEO of aCGT Vector, discusses the company’s plans to advance cell therapy manufacturing and why they selected Dublin to build the business.

Stem Cell Therapies: Close to Transforming Promise into Real Patient Outcomes

Cynthia A. Challener, Ph.D.

Pharma's Almanac

PAO-07-26-PA-11Jul 22, 2026

In Vivo Selection

Repairing More Tissue Than You Edit: What In Vivo Selection Could Mean for Gene Therapy

David Alvaro, Ph.D.

Pharma's Almanac

PAO-06-26-PA-14Jul 13, 2026

Genome Engineering

Aiming for More than Single-Base Corrections: The Technologies Opening the Genome to Therapeutic Cargo

David Alvaro, Ph.D.

Pharma's Almanac

PAO-06-26-PA-16Jun 29, 2026

Microbiome Editing

Editing the Microbiome in Place: From Engineered Probiotics to Programmable Ecological Therapies

David Alvaro, Ph.D.

Pharma's Almanac

PAO-06-26-PA-15Jun 22, 2026

Pathfinder

Lipid Nanoparticles vs. Viral Vectors for Gene Delivery: Which Platform Is Better?

Pharma's Almanac

PAO-26-PF-11Jun 12, 2026

Continuous VV

The Stepwise Future of Continuous Viral Vector Manufacturing

David Alvaro, Ph.D.

Pharma's Almanac

PAO-05-26-PA-12Jun 1, 2026

Pathfinder

AAV vs. Lentiviral Vectors: Which Viral Vector Is Better for Gene Therapy?

Pharma's Almanac

PAO-26-PF-09May 29, 2026

Roundtable

How is the increasing complexity of modalities reshaping CDMO differentiation and specialization strategies?

Pharma's Almanac

PAO-05-26-RT-02May 27, 2026

HACs

Synthetic Chromosome Therapeutics: Expanding Genomic Medicine Beyond the Limits of Gene Therapy

David Alvaro, Ph.D.

Pharma's Almanac

PAO-05-26-PA-02May 11, 2026

Pathfinder

CRISPR vs. Base Editing vs. Prime Editing: Which Genome Editing Technology Is Best?

Pharma's Almanac

PAO-26-PF-05May 1, 2026

Pathfinder

AAV vs. Non-Viral Gene Delivery: Which Is Better for In Vivo Gene Therapy?

Pharma's Almanac

PAO-26-PF-01Apr 3, 2026

Neuro CMC

Producing Therapies for the Brain: Manufacturing and Formulation Challenges for CNS Biologics

David Alvaro, Ph.D.

Pharma's Almanac

PAO-04-26-PA-03Apr 3, 2026

Nice Insight is the market research division of That's Nice LLC, the leading marketing agency serving life sciences.

Explore

About Us Nice Insight That's Nice

Reach Our Team

My Account

Subscribe for the newsletter

Subscribe for the Newsletter

Mobile Navigation

Innovating Cell Therapy Manufacturing

Related Content

Stem Cells

Stem Cell Therapies: Close to Transforming Promise into Real Patient Outcomes

Cynthia A. Challener, Ph.D.

Pharma's Almanac

In Vivo Selection

Repairing More Tissue Than You Edit: What In Vivo Selection Could Mean for Gene Therapy

David Alvaro, Ph.D.

Pharma's Almanac

Genome Engineering

Aiming for More than Single-Base Corrections: The Technologies Opening the Genome to Therapeutic Cargo

David Alvaro, Ph.D.

Pharma's Almanac

Microbiome Editing

Editing the Microbiome in Place: From Engineered Probiotics to Programmable Ecological Therapies

David Alvaro, Ph.D.

Pharma's Almanac

Pathfinder

Lipid Nanoparticles vs. Viral Vectors for Gene Delivery: Which Platform Is Better?

Pharma's Almanac

Continuous VV

The Stepwise Future of Continuous Viral Vector Manufacturing

David Alvaro, Ph.D.

Pharma's Almanac

Pathfinder

AAV vs. Lentiviral Vectors: Which Viral Vector Is Better for Gene Therapy?

Pharma's Almanac

Roundtable

How is the increasing complexity of modalities reshaping CDMO differentiation and specialization strategies?

Pharma's Almanac

HACs

Synthetic Chromosome Therapeutics: Expanding Genomic Medicine Beyond the Limits of Gene Therapy

David Alvaro, Ph.D.

Pharma's Almanac

Pathfinder

CRISPR vs. Base Editing vs. Prime Editing: Which Genome Editing Technology Is Best?

Pharma's Almanac

Pathfinder

AAV vs. Non-Viral Gene Delivery: Which Is Better for In Vivo Gene Therapy?

Pharma's Almanac

Neuro CMC

Producing Therapies for the Brain: Manufacturing and Formulation Challenges for CNS Biologics

David Alvaro, Ph.D.

Pharma's Almanac

Related Content

Stem Cells

Stem Cell Therapies: Close to Transforming Promise into Real Patient Outcomes

Cynthia A. Challener, Ph.D.

Pharma's Almanac

In Vivo Selection

Repairing More Tissue Than You Edit: What In Vivo Selection Could Mean for Gene Therapy

David Alvaro, Ph.D.

Pharma's Almanac

Genome Engineering

Aiming for More than Single-Base Corrections: The Technologies Opening the Genome to Therapeutic Cargo

David Alvaro, Ph.D.

Pharma's Almanac

Microbiome Editing

Editing the Microbiome in Place: From Engineered Probiotics to Programmable Ecological Therapies

David Alvaro, Ph.D.

Pharma's Almanac

Pathfinder

Lipid Nanoparticles vs. Viral Vectors for Gene Delivery: Which Platform Is Better?

Pharma's Almanac

Continuous VV

The Stepwise Future of Continuous Viral Vector Manufacturing

David Alvaro, Ph.D.

Pharma's Almanac

Pathfinder

AAV vs. Lentiviral Vectors: Which Viral Vector Is Better for Gene Therapy?

Pharma's Almanac

Roundtable

How is the increasing complexity of modalities reshaping CDMO differentiation and specialization strategies?

Pharma's Almanac

HACs

Synthetic Chromosome Therapeutics: Expanding Genomic Medicine Beyond the Limits of Gene Therapy

David Alvaro, Ph.D.